A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes

PHASE3CompletedINTERVENTIONAL
Enrollment

559

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

October 31, 2007

Study Completion Date

December 31, 2007

Conditions
Bipolar Disorder
Interventions
DRUG

Risperdal Consta

12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks

DRUG

Placebo

Matching placebo intramuscular (IM) injection every 2 weeks

Trial Locations (51)

Unknown

Little Rock

La Mesa

National City

Washington D.C.

Bradenton

Hialeah

Lake Charles

Towson

Clementon

Lyndhurst

Oklahoma City

Philadelphia

DeSoto

Richmond

Neunkirchen

Bangalore

Hyderabad

Manipal

Johor Bahru

Kota Bharu

Kuala Lumpur

Choroszcz

Gdansk

Swiecie Poland

Tuszyn

Lipetsk

Moscow

Moscow Region

Moscow Russia

Nizny Novgorod

Saint Petersburg

Samara

Saratov

St-Petresburg

Bratislava

Košice

Rimavská Sobota

Barcelona

Madrid

Taichung

Tainan City

Taipei

Taoyuan District

Dnipro

Hlevakha

Kharkiv

Kiev

Lviv

Odesa

Simferopol

Vinnitsa

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00132678 - A Study of the Safety and Efficacy of Injectable Risperidone in the Prevention of Bipolar Mood Episodes | Biotech Hunter | Biotech Hunter